ES2627954T3 - Sistema de expresión en CHO - Google Patents
Sistema de expresión en CHO Download PDFInfo
- Publication number
- ES2627954T3 ES2627954T3 ES13732112.1T ES13732112T ES2627954T3 ES 2627954 T3 ES2627954 T3 ES 2627954T3 ES 13732112 T ES13732112 T ES 13732112T ES 2627954 T3 ES2627954 T3 ES 2627954T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- cho
- cell line
- sequence
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 66
- 102000005396 glutamine synthetase Human genes 0.000 claims abstract description 153
- 108020002326 glutamine synthetase Proteins 0.000 claims abstract description 153
- 239000013598 vector Substances 0.000 claims abstract description 153
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 88
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 88
- 108020004414 DNA Proteins 0.000 claims abstract description 47
- 102000053602 DNA Human genes 0.000 claims abstract description 47
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 38
- 239000002773 nucleotide Substances 0.000 claims abstract description 19
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 19
- 239000013604 expression vector Substances 0.000 claims abstract description 17
- 241000699802 Cricetulus griseus Species 0.000 claims abstract description 14
- 239000003623 enhancer Substances 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 12
- 210000001672 ovary Anatomy 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 128
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 62
- 241000282414 Homo sapiens Species 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 27
- 101000888841 Homo sapiens Glutamine synthetase Proteins 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 238000010367 cloning Methods 0.000 claims description 16
- 101000888808 Canis lupus familiaris Glutamine synthetase Proteins 0.000 claims description 14
- 238000001890 transfection Methods 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 5
- 230000002477 vacuolizing effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 241000701022 Cytomegalovirus Species 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 108020004635 Complementary DNA Proteins 0.000 description 10
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 10
- 102000044890 human EPO Human genes 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 102000003951 Erythropoietin Human genes 0.000 description 7
- 108090000394 Erythropoietin Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229940105423 erythropoietin Drugs 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 241000219195 Arabidopsis thaliana Species 0.000 description 3
- 241000255601 Drosophila melanogaster Species 0.000 description 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241000269368 Xenopus laevis Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 235000008979 vitamin B4 Nutrition 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101150074355 GS gene Proteins 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- -1 such variations Chemical compound 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WBLQOEONNIZSFM-UHFFFAOYSA-N CS(=N)=O Chemical compound CS(=N)=O WBLQOEONNIZSFM-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108700032892 Drosophila seq Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101900067218 Human cytomegalovirus Viral transcription factor IE2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 101100015007 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GLN1 gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/55—Vectors comprising a special origin of replication system from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305677 | 2012-06-14 | ||
| EP12305677.2A EP2674495A1 (en) | 2012-06-14 | 2012-06-14 | CHO expression system |
| PCT/EP2013/062400 WO2013186371A1 (en) | 2012-06-14 | 2013-06-14 | Cho expression system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2627954T3 true ES2627954T3 (es) | 2017-08-01 |
Family
ID=48700539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13732112.1T Active ES2627954T3 (es) | 2012-06-14 | 2013-06-14 | Sistema de expresión en CHO |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9334489B2 (enExample) |
| EP (2) | EP2674495A1 (enExample) |
| CN (2) | CN104540950A (enExample) |
| AR (1) | AR091418A1 (enExample) |
| AU (1) | AU2013276467B2 (enExample) |
| CA (1) | CA2876550C (enExample) |
| DK (1) | DK2861741T3 (enExample) |
| ES (1) | ES2627954T3 (enExample) |
| HU (1) | HUE032968T2 (enExample) |
| IN (1) | IN2014KN02823A (enExample) |
| MX (1) | MX353499B (enExample) |
| SG (1) | SG11201408051VA (enExample) |
| TW (1) | TWI605123B (enExample) |
| UY (1) | UY34860A (enExample) |
| WO (1) | WO2013186371A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR102333A1 (es) | 2014-08-19 | 2017-02-22 | Regeneron Pharma | Selectividad eficiente de proteínas recombinadas |
| SG11201702516UA (en) * | 2014-10-23 | 2017-04-27 | Sanofi Sa | Novel selection marker for cell transfection and protein production |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
| WO2018047154A1 (en) | 2016-09-07 | 2018-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
| CN111093641A (zh) | 2017-05-24 | 2020-05-01 | 托埃瑞斯有限责任公司 | 谷氨酰胺合成酶用于治疗高氨血症的用途 |
| IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
| CN108085337B (zh) * | 2017-12-28 | 2020-10-16 | 未名生物医药有限公司 | 一种gs表达系统细胞株的筛选方法 |
| CN109988777A (zh) * | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | 谷氨酰胺合成酶基因以及应用 |
| US20220356487A1 (en) * | 2019-06-07 | 2022-11-10 | Biocon Biologics India Limited | Mammalian expression vectors |
| IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
| IL301442A (en) | 2020-09-21 | 2023-05-01 | Sanofi Sa | Production of a recombinant Chinese hamster ovary cell line (CHO) for the production of a high-yield therapeutic protein |
| EP4384623A4 (en) * | 2021-08-03 | 2025-09-24 | Shanghai Zhenge Biotechnology Co Ltd | SELECTABLE MARKERS FOR EUKARYOTIC EXPRESSION SYSTEM |
| CN118804978A (zh) * | 2021-12-27 | 2024-10-18 | 上海臻格生物技术有限公司 | 用于重组生产系统的新型标志物 |
| CN115287300A (zh) * | 2022-08-11 | 2022-11-04 | 无锡多宁生物科技有限公司 | 一种增强ExpiCHO细胞瞬时转染抗体表达的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8924021D0 (en) * | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| KR100267720B1 (ko) * | 1997-12-29 | 2001-03-02 | 박호군 | 사람 글루타민 합성효소 유전자를 포함하는 발현벡터 및 이를 이용하여 동물세포에서 에리트로포이에틴을 고수율로 생산하는 방법 |
| GB0216648D0 (en) * | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| JP4764818B2 (ja) * | 2003-04-11 | 2011-09-07 | メディミューン，エルエルシー | 組換えｉｌ−９抗体およびその使用 |
| US7244616B2 (en) * | 2003-06-27 | 2007-07-17 | Bayer Pharmaceuticals Corporation | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
| EP2298890A1 (en) * | 2004-12-30 | 2011-03-23 | Agency for Science, Technology and Research | Chinese hamster apoptosis-related genes |
| GB0508154D0 (en) * | 2005-04-22 | 2005-06-01 | Lonza Biologics Plc | Mammalian expression vector comprising the mCMV promoter and first intron of hCMV major immediate early gene |
| GB0510277D0 (en) * | 2005-05-20 | 2005-06-29 | Lonza Biologics Plc | High-level expression of recombinant antibody in a mammalian host cell |
| EP2109674A2 (en) * | 2007-01-08 | 2009-10-21 | Millipore Corporation | High expression cell line that eliminates gene amplification |
| LT2592148T (lt) * | 2007-10-12 | 2018-12-10 | F. Hoffmann-La Roche Ag | Baltymų ekspresavimas iš kelių nukleorūgščių |
| MY158903A (en) | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
-
2012
- 2012-06-14 EP EP12305677.2A patent/EP2674495A1/en not_active Withdrawn
-
2013
- 2013-06-12 AR ARP130102062 patent/AR091418A1/es unknown
- 2013-06-14 IN IN2823KON2014 patent/IN2014KN02823A/en unknown
- 2013-06-14 MX MX2014015280A patent/MX353499B/es active IP Right Grant
- 2013-06-14 WO PCT/EP2013/062400 patent/WO2013186371A1/en not_active Ceased
- 2013-06-14 TW TW102121230A patent/TWI605123B/zh active
- 2013-06-14 CN CN201380042643.6A patent/CN104540950A/zh active Pending
- 2013-06-14 HU HUE13732112A patent/HUE032968T2/en unknown
- 2013-06-14 AU AU2013276467A patent/AU2013276467B2/en active Active
- 2013-06-14 SG SG11201408051VA patent/SG11201408051VA/en unknown
- 2013-06-14 UY UY0001034860A patent/UY34860A/es not_active Application Discontinuation
- 2013-06-14 CA CA2876550A patent/CA2876550C/en active Active
- 2013-06-14 CN CN201711180397.7A patent/CN107881151A/zh active Pending
- 2013-06-14 DK DK13732112.1T patent/DK2861741T3/en active
- 2013-06-14 EP EP13732112.1A patent/EP2861741B1/en active Active
- 2013-06-14 ES ES13732112.1T patent/ES2627954T3/es active Active
- 2013-06-14 US US14/407,836 patent/US9334489B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201408051VA (en) | 2015-01-29 |
| TWI605123B (zh) | 2017-11-11 |
| TW201402817A (zh) | 2014-01-16 |
| WO2013186371A1 (en) | 2013-12-19 |
| CA2876550C (en) | 2021-07-13 |
| MX2014015280A (es) | 2015-06-23 |
| DK2861741T3 (en) | 2017-07-17 |
| AU2013276467A1 (en) | 2015-01-15 |
| US9334489B2 (en) | 2016-05-10 |
| CA2876550A1 (en) | 2013-12-19 |
| EP2674495A1 (en) | 2013-12-18 |
| MX353499B (es) | 2018-01-16 |
| EP2861741A1 (en) | 2015-04-22 |
| AR091418A1 (es) | 2015-02-04 |
| UY34860A (es) | 2014-01-31 |
| HUE032968T2 (en) | 2017-11-28 |
| US20150140607A1 (en) | 2015-05-21 |
| CN104540950A (zh) | 2015-04-22 |
| EP2861741B1 (en) | 2017-04-12 |
| AU2013276467B2 (en) | 2018-08-30 |
| IN2014KN02823A (enExample) | 2015-05-08 |
| CN107881151A (zh) | 2018-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2627954T3 (es) | Sistema de expresión en CHO | |
| DK2441831T3 (en) | PROCEDURE FOR PRODUCING PROTEIN | |
| JP5701061B2 (ja) | 哺乳類発現ベクター | |
| US12203103B2 (en) | Selection marker for cell transfection and protein production | |
| KR20100014724A (ko) | 숙주 세포에서 재조합 단백질의 발현을 증강시키기 위한 재조합 발현 벡터 요소(ｒＥＶＥ) | |
| ES2230908T3 (es) | Procedimiento para la preparacion de celulas recombinantes. | |
| WO2000058499A1 (fr) | Procede pour la production d'anticorps monoclonal | |
| ES2871818T3 (es) | Métodos de selección celular y modificación del metabolismo celular | |
| JP2015513406A (ja) | 改変グルタミン合成酵素をコードするポリヌクレオチドを含む発現ベクターおよびこれを用いた標的タンパク質の製造方法 | |
| CN109072236A (zh) | 用于生产分泌蛋白质的哺乳动物细胞 | |
| AU2020242966B2 (en) | Novel selection marker-comprising cell line and uses thereof for protein production | |
| JP2013504304A (ja) | 改善されたヒト長ペントラキシン３発現系及びその使用 | |
| US12529071B2 (en) | Selection marker-comprising cell line and uses thereof for protein production | |
| WO2025128343A1 (en) | Protein expression using trans-splicing and split selectable markers |